RayKnowChina Research Map
Shortlist0

BeijingCapital Medical University

Xuanwu Hospital

首都医科大学宣武医院

Listed for 20 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Xuanwu Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatocellular carcinoma肝细胞癌15 papers led
  2. Stomach cancer胃癌5 papers led
  3. Retinoblastoma视网膜母细胞瘤0 papers led
  4. Chordoma脊索瘤7 papers led
  5. Osteosarcoma骨肉瘤1 paper led
  6. Neuroblastoma神经母细胞瘤3 papers led
  7. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
  8. Beta thalassaemiaβ 地中海贫血1 paper led
  9. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  10. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病5 papers led2 open trials led
  11. IgG4-related diseaseIgG4相关性疾病2 papers led
  12. Myasthenia gravis重症肌无力16 papers led1 open trial led
  13. Moyamoya disease烟雾病7 papers led
  14. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎9 papers led
  15. Takayasu arteritis大动脉炎6 papers led
  16. Amyotrophic lateral sclerosis肌萎缩侧索硬化症7 papers led
  17. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  18. Behçet disease白塞病0 papers led
  19. IgA nephropathyIgA 肾病2 papers led
  20. Niemann–Pick disease type C尼曼-匹克病 C 型1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatoblastoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Wilson disease, Biliary atresia, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 15 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
15
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 3320232024: 5520242025: 332025

17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionLocal treatment (ablation, TACE, HAIC)
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicine
Papers it led15
  1. Preoperative prediction of Glypican-3 in hepatocellular carcinoma by two-dimensional ultrasound, contrast-enhanced ultrasound and microflow imaging.2025Clinical hemorheology and microcirculation
  2. Machine learning-based tumor associated macrophages polarity signature predicts prognosis and treatment response in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  3. Hypoxia-Activated Imidazoquinoline Prodrug Nanoparticles Potentiate Radiofrequency Ablation-Mediated Antitumor Immunity Against Hepatocellular Carcinoma.2025Small (Weinheim an der Bergstrasse, Germany)
  4. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-2024Annals of surgical oncology
  5. Diagnostic values of contrast-enhanced MRI and contrast-enhanced CT for evaluating the response of hepatocellular carcinoma after transarterial chemoembolisation: a meta-analysis.2024BMJ openFree full text
  6. The value of contrast-enhanced ultrasound combined with microflow imaging in predicting microvascular invasion of hepatocellular carcinoma before operation.2024Clinical hemorheology and microcirculation
  7. Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis.2024Frontiers in immunologyFree full text
  8. Developments and current status of cell-free DNA in the early detection and management of hepatocellular carcinoma.2024Journal of gastroenterology and hepatology
  9. Comprehensive analysis of anoikis-related lncRNAs for predicting prognosis and response of immunotherapy in hepatocellular carcinoma.2023IET systems biologyFree full text
  10. Intratumoral perfusion may affect microwave ablation area of hepatocellular carcinoma.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  11. Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.2023MedicineFree full text
  12. Exploration and validation of the prognostic value of RNA-binding proteins in hepatocellular carcinoma.2022European review for medical and pharmacological sciences
  13. Fluorescent Imaging-Guided Chemo- and Photodynamic Therapy of Hepatocellular Carcinoma with HCPT@NMOFs-RGD Nanocomposites.2022International journal of nanomedicineFree full text
  14. Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients.2021Bioscience reportsFree full text
  15. Blockade of Erythropoietin-Producing Human Hepatocellular Carcinoma Receptor B1 in Spinal Dorsal Horn Alleviates Visceral Pain in Rats.2021Pain research & managementRCTFree full text
Chinese-language papers (not in the count)1
  1. [Exploration of cystathionine β-synthase and cystathionine γ-lyase gene expression poor prognostic predictive value with the application of bioinformatics data mining in liver cancer].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver CancerWithdrawnNCT05292443Study siteStart 2021-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 5 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.05%.

Papers led
5
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025

15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & AIEarly detection & endoscopyPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Beijing for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 7 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 6.7%.

Papers led
7
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 3320242025: 222025

11 hospitals in Beijing for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryENT / head & neck surgery

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 002025

24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Beijing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL PatientsStatus unknownNCT03902197Lead sponsorPhase 2Start 2019-04

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

10 hospitals in Beijing for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 5 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.0%.

Papers led
5
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 222025

12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07762872

    Age 18 years to Not stated (registered criteria)

    Led by Xuanwu HospitalBeijing

  2. Not yet recruiting
    Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
    Phase
    Early phase 1
    Started
    2025-02
    Registry
    NCT06485232

    Age 18 years to 75 years (registered criteria)

    Led by Xuanwu HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImagingAcute attack treatmentAntibodies & diagnosis
Departments in papersRadiology / nuclear medicinePathology / laboratory medicineNeurology
Papers it led5
  1. Progressive brain function changes in patients with neuromyelitis optica: insights from resting-state fMRI.2025Brain imaging and behavior
  2. Changes in brain functional connectivity and clinical correlations in neuromyelitis optica spectrum disorder: a longitudinal resting-state fMRI study.2025European journal of medical researchFree full text
  3. Factors influencing the degree of disability in patients with neuromyelitis optica spectrum disorders.2023European journal of medical researchFree full text
  4. Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS.2023Multiple sclerosis and related disorders
  5. Multi-parametric MRI phenotype with trustworthy machine learning for differentiating CNS demyelinating diseases.2021Journal of translational medicineFree full text
All its trials on ClinicalTrials.gov, any status7
  1. Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.Not yet recruitingNCT06485232Lead sponsorEarly phase 1Start 2025-02
  2. Inebilizumab in Acute Neuromyelitis Optica Spectrum DisordersStatus unknownNCT05891379Lead sponsorStart 2024-07
  3. An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult PatientsTerminatedNCT05356858Lead sponsorPhase 2Start 2022-05
  4. National, Multicentric Registry Study on Neuroimmunological Diseases in ChinaStatus unknownNCT06443333Lead sponsorStart 2020-12
  5. Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum DisordersStatus unknownNCT02021825Lead sponsorPhase 4Start 2009-03
  6. A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSDRecruitingNCT07762872Lead (inferred)Start 2026-07
  7. Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)CompletedNCT05551598Study sitePhase 2Start 2022-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgeryNeurology
Papers it led2
  1. Otological IgG4-Related Disease With Inner Ear Involvement: A Case Report and Review of Literature.2022Ear, nose, & throat journal
  2. Radiological Features of IgG4-Related Disease in the Head, Neck, and Skull Base.2022ORL; journal for oto-rhino-laryngology and its related specialties
Chinese-language papers (not in the count)1
  1. [Clinical analysis of immunoglobulin G4-related disease with neurological involvement].2025Zhonghua nei ke za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 16 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 3.2%.

Papers led
16
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 4420232024: 3320242025: 442025

11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
    Phase
    Early phase 1
    Started
    2025-02
    Registry
    NCT06485232

    Age 18 years to 75 years (registered criteria)

    Led by Xuanwu HospitalBeijing

  2. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

  3. Recruiting
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06463587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi

  4. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStandard immunotherapyBiologic & complement drugsAntibodies & diagnosis
Departments in papersNeurologySurgery (general/hepatobiliary/pancreatic)
Papers it led16
  1. Dynamic Changes in Peripheral Immune Cells During Efgartigimod Treatment in Naive Generalized Myasthenia Gravis.2025CNS neuroscience & therapeuticsFree full text
  2. Peripheral immune profiling highlights a dynamic role of low-density granulocytes in myasthenia gravis.2025Journal of autoimmunity
  3. Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study.2025Journal of neurologyFree full text
  4. Platelet activation plays a pro-inflammatory role in myasthenia gravis.2025Nature communicationsFree full text
  5. Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer patient: a case report and literature review.2024Journal of neurology
  6. Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis.2024Journal of translational medicineFree full text
  7. Environmental factors affecting the risk of generalization for ocular-onset myasthenia gravis: a nationwide cohort study.2024QJM : monthly journal of the Association of Physicians
  8. Mortality of myasthenia gravis: a national population-based study in China.2023Annals of clinical and translational neurologyFree full text
  9. Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis.2023Annals of clinical and translational neurologyFree full text
  10. Genetically predicted effects of physical activity and sedentary behavior on myasthenia gravis: evidence from mendelian randomization study.2023BMC neurologyFree full text
  11. Autoantibody levels as biomarkers of disease activity in the management of myasthenia gravis.2023European journal of neurology
  12. Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study.2022Frontiers in immunologyFree full text
  13. A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis.2022Frontiers in immunologyRCTFree full text
  14. Involvement of Ocular Muscles in Patients With Myasthenia Gravis With Nonocular Onset.2022Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  15. CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients.2021Journal of neuroimmunology
  16. Risk Factors for Postoperative Myasthenic Crisis After Thymectomy in Patients With Myasthenia Gravis.2021The Journal of surgical research
Chinese-language papers (not in the count)1
  1. [Analyses of the risk factors of delayed extubation after extended thymectomy in patients with myasthenia gravis].2025Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status8
  1. Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.Not yet recruitingNCT06485232Lead sponsorEarly phase 1Start 2025-02
  2. National, Multicentric Registry Study on Neuroimmunological Diseases in ChinaStatus unknownNCT06443333Lead sponsorStart 2020-12
  3. Clinical Prognosis and Progression of Myasthenia Gravis PatientsStatus unknownNCT04101578Lead (inferred)Start 2017-02
  4. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  5. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RecruitingNCT06463587Study sitePhase 3Start 2024-06
  6. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  7. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisActive, not recruitingNCT06298552Study sitePhase 3Start 2024-04
  8. Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Study sitePhase 3Start 2023-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 7 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 2.0%.

Papers led
7
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 0020232024: 1120242025: 112025

8 hospitals in Beijing for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

  2. Recruiting
    Registry of Multicenter Brain-Heart Comorbidity in China
    Phase
    Not given
    Started
    2012-01
    Registry
    NCT05961748

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 4 listed hospitals as study sitesBeijing, Harbin, Shanghai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & blood flowStroke & bleeding outcomesRevascularisation surgery
Departments in papersNeurologyNeurosurgeryRadiology / nuclear medicine
Papers it led7
  1. The Role of TCD in Assessing Postoperative Collateral Development and Long-Term Clinical Outcome in Moyamoya Disease.2025CNS neuroscience & therapeuticsFree full text
  2. Remote ischemic conditioning prevents ischemic cerebrovascular events in children with moyamoya disease: a randomized controlled trial.2024World journal of pediatrics : WJPRCTFree full text
  3. Imaging features of adult moyamoya disease patients with anterior intracerebral hemorrhage based on high-resolution magnetic resonance imaging.2022Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and MetabolismFree full text
  4. Characteristics of cerebral ischemic stroke based on moyamoya disease and atherosclerosis-associated intracranial arterial stenosis.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  5. Vascular Architecture Characters and Changes of Pediatric Moyamoya Disease after Combined Bypass Surgery.2022Neuropediatrics
  6. Pathophysiological Significance of Neutrophilic Transfer RNA-Derived Small RNAs in Asymptomatic Moyamoya Disease.2021CellsFree full text
  7. Validation of choroidal anastomosis on high-resolution magnetic resonance imaging as an imaging biomarker in hemorrhagic moyamoya disease.2021European radiology
All its trials on ClinicalTrials.gov, any status4
  1. The Safety and Efficacy of RIC on Adult Moyamoya DiseaseCompletedNCT04012268Lead (inferred)N/AStart 2019-07
  2. The Effect of RIC on TIA/Stroke in Children With Moyamoya DiseaseStatus unknownNCT03821181Lead (inferred)N/AStart 2019-12
  3. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya SyndromeRecruitingNCT07894107Study siteStart 2026-08
  4. Registry of Multicenter Brain-Heart Comorbidity in ChinaRecruitingNCT05961748Study siteStart 2012-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 9 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 3.4%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 1120232024: 2220242025: 112025

13 hospitals in Beijing for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led9
  1. Clinical characterization of diseases associated with anti-N-methyl-D-aspartate receptor encephalitis combined with anti-myelin oligodendrocyte glycoprotein antibodies in adults.2025Journal of neurology
  2. Psychiatric features in NMDAR and LGI1 antibody-associated autoimmune encephalitis.2024European archives of psychiatry and clinical neuroscience
  3. Clinical features of COVID-19-related encephalitis: comparison with the features of herpes virus encephalitis and autoimmune encephalitis.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Status dystonicus in adult patients with anti-N-methyl-D-aspartate-acid receptor encephalitis.2023Journal of neurology
  5. Characteristics and Outcomes of Paroxysmal Sympathetic Hyperactivity in Anti-NMDAR Encephalitis.2022Frontiers in immunology
  6. Focal motor seizure as a presenting symptom in anti-mGluR5 encephalitis: A case report.2022Seizure
  7. Clinical efficacy of plasma exchange in patients with autoimmune encephalitis.2021Annals of clinical and translational neurology
  8. Presence of Anti-Thyroid Antibodies Correlate to Worse Outcome of Anti-NMDAR Encephalitis.2021Frontiers in immunology
  9. Overlapping syndrome of anti-N-methyl-D-aspartate receptor encephalitis and anti-myelin oligodendrocyte glycoprotein inflammatory demyelinating diseases: A distinct clinical entity?2021Multiple sclerosis and related disorders
Chinese-language papers (not in the count)1
  1. [An adult case of pseudotumor-like overlapping syndrome of MOG antibody-related disease and NMDAR encephalitis].2025Zhonghua nei ke za zhi
Earlier papers (2016–2020)6
  1. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.2019Multiple sclerosis and related disorders
  2. Efficacy of Therapeutic Plasma Exchange in Patients with Severe Refractory Anti-NMDA Receptor Encephalitis.2019Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
  3. Reply.2018AJNR. American journal of neuroradiology
  4. Clinical Characteristics and Prognosis of Severe Anti-N-methyl-D-aspartate Receptor Encephalitis Patients.2018Neurocritical care
  5. Analysis of electroencephalogram characteristics of anti-NMDA receptor encephalitis patients in China.2017Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  6. [Analysis of clinical characteristics and outcomes of mechanically ventilated patients with anti-N-methyl-D-aspartate receptor encephalitis].2017Zhonghua yi xue za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 6 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 3.2%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025

30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunologyRadiology / nuclear medicine
Papers it led6
  1. An update on stroke and transient ischemic attack in Takayasu arteritis: A systematic review and meta-analysis.2026Joint bone spine
  2. Clinical value of diagnosing ischaemic stroke in patients with Takayasu's arteritis combining multiple arterial occlusion and high-grade enhancement.2025Clinical and experimental rheumatology
  3. Cerebral Perfusion Features in Takayasu Arteritis: Insights From pCASL MRI.2025International journal of rheumatic diseases
  4. Childhood-onset versus adult-onset Takayasu arteritis: A study of 239 patients from China.2025Joint bone spine
  5. Long-term outcomes of angioplasty for pediatric renovascular hypertension: A single-center experience.2023Vascular
  6. Covered Cheatham-Platinum Stent for Treatment of Descending Thoracic Aortic Stenosis Caused by Takayasu Arteritis in Two Children.2022Annals of vascular surgery
Earlier papers (2016–2020)2
  1. Contemporary Challenges of Acute Ischemic Stroke in Takayasu Arteritis.2020Stroke
  2. Regional cerebral oxygen saturation guided cerebral protection in a parturient with Takayasu's arteritis undergoing cesarean section: a case report.2016Journal of clinical anesthesia
All its trials on ClinicalTrials.gov, any status5
  1. Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1)Status unknownNCT06178419Lead sponsorN/AStart 2024-01
  2. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Study sitePhase 4Start 2026-04
  3. Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu ArteritisStatus unknownNCT05151848Study sitePhase 4Start 2022-01
  4. A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)Active, not recruitingNCT04161898Study sitePhase 3Start 2020-02
  5. Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's ArteritisCompletedNCT03096275Study sitePhase 3Start 2017-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 7 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.9%.

Papers led
7
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 1120232024: 1120242025: 112025

19 hospitals in Beijing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyRadiology / nuclear medicine
Papers it led7
  1. Characterization and chemoproteomic profiling of protein O-GlcNAcylation in SOD1-G93A mouse model.2025Molecular medicine (Cambridge, Mass.)
  2. Different baseline functional patterns of the frontal cortex in amyotrophic lateral sclerosis patients with Corticospinal tract hyperintensity.2024Brain research
  3. Proteomics analysis indicates the involvement of immunity and inflammation in the onset stage of SOD1-G93A mouse model of ALS.2023Journal of proteomics
  4. Identification of TARDBP Gly298Ser as a founder mutation for amyotrophic lateral sclerosis in Southern China.2022BMC medical genomics
  5. Different sensorimotor mechanism in fast and slow progression amyotrophic lateral sclerosis.2022Human brain mapping
  6. The associations between plasma soluble Trem1 and neurological diseases: a Mendelian randomization study.2022Journal of neuroinflammation
  7. Unusual electrophysiological findings in a Chinese ALS 4 family with SETX-L389S mutation: a three-year follow-up.2021Journal of neurology
Chinese-language papers (not in the count)1
  1. [Clinical analysis of a motor neuron disease-like phenotype associated with anti-IgLON5 disease].2025Zhonghua nei ke za zhi
Earlier papers (2016–2020)8
  1. Rare, low-frequency and common coding variants of ARHGEF28 gene and their association with sporadic amyotrophic lateral sclerosis.2020Neurobiology of aging
  2. Mendelian randomization study to evaluate the effects of interleukin-6 signaling on four neurodegenerative diseases.2020Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  3. Activation of the Notch Signaling Pathway and Cellular Localization of Notch Signaling Molecules in the Spinal Cord of SOD1-G93A ALS Model Mice.2020Neuroscience
  4. The Role of Iron in Amyotrophic Lateral Sclerosis.2019Advances in experimental medicine and biology
  5. Presence of antibodies against low-density lipoprotein receptor-related protein 4 and impairment of neuromuscular junction in a Chinese cohort of amyotrophic lateral sclerosis.2019Chinese medical journal
  6. The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis.2018Drug delivery
  7. Total intravenous anesthesia without muscle relaxant in a parturient with amyotrophic lateral sclerosis undergoing cesarean section: A case report.2017Journal of clinical anesthesia
  8. Atypical familial amyotrophic lateral sclerosis with initial symptoms of pain or tremor in a Chinese family harboring VAPB-P56S mutation.2016Journal of neurology
All its trials on ClinicalTrials.gov, any status3
  1. hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative DiseasesNot yet recruitingNCT06607900Lead sponsorPhase 1Start 2025-07
  2. Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALSStatus unknownNCT06598202Lead sponsorPhase 1/Phase 2Start 2024-12
  3. Effects of L-Carnitine in Amyotrophic Lateral Sclerosis Patients With CHCHD10 MutationsCompletedNCT06849115Lead (inferred)Phase 4Start 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

11 hospitals in Beijing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11
  2. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedNCT04609397Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Niemann–Pick disease type C

尼曼-匹克病 C 型

Led 1 of the 16 English-language PubMed papers on Niemann–Pick disease type C with an author in mainland China, 2021–2025: 6.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Beijing for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C

No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Central sleep apnea and daytime sleepiness in Niemann-Pick type C disease: a report of 2 cases.2023Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

首都医科大学宣武医院

Xuanwu Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.
Xuanwu Hospital of Capital Medical University; Xuanwu Hospital Capital Medical University; XuanWu hospital; Xiongan Xuanwu Hospital; Beijing Xuanwu Hospital; Xuanwu Hospital (S.H; Neurology of Xuanwu Hospital; Xuanwu Hospital (S.L.)

Suggest a correctionDownload the data